AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or ...

Immunotherapy has emerged as one of the major options for cancer treatment in the past decade. With the successful application of immune checkpoint inhibitors and the introduction of immune regulatory ...

Targeted CRISPR lipid nanoparticles eliminated 50% of tumors in mice with head and neck cancer.

The pharma is paying up to $1 billion to buy the Belgian startup, whose technology it sees as useful in treating cancer and ...

EsoBiotec’s platform has the potential to eliminate the complex and time-consuming process for manufacturing, helping to make CAR-T cell therapies more accessible.

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its ...

To date, the project has successfully developed self-assembled nanoparticles capable of loading and releasing anti-cancer ...

In vivo cell therapy is a new way of delivering ... potential of such a technology combination and the ability to treat cancer patients moving forward.” All this leaves one big question for ...

GeekWire Award finalists for Health Innovation of the Year are dominated by ventures that aim to outwit cancer with ...